Swan-Ganz
Payments companies reported to CMS as associated with Swan-Ganz. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Swan-Ganz, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Swan-Ganz
These are the largest totals companies reported as associated with Swan-Ganz. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Taipale | Saginaw, MI | Cardiovascular Disease | $498.48 |
| Brian Renard | Troy, MI | Cardiovascular Disease | $468.84 |
| Richard Bloomingdale | Royal Oak, MI | Internal Medicine | $442.98 |
| Elvis Cami | Royal Oak, MI | Cardiovascular Disease | $442.98 |
| Sorcha Allen | Royal Oak, MI | Cardiovascular Disease | $442.98 |
| Jawwad Yusuf | Dallas, TX | Interventional Cardiology | $249.24 |
| Matthew Waldron | Sarasota, FL | Anesthesiology | $207.62 |
| Fernando Yepes | Kearney, NE | Critical Care Medicine (Anesthesiology) | $205.19 |
| David Kustera | Manhasset, NY | Anesthesiology | $165.66 |
| Yefim Vilnits | New York, NY | Critical Care Medicine (Anesthesiology) | $165.66 |
Prescribed Swan-Ganz?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.